慢性HBV感染免疫耐受期应重新评估诊断标准并将研究重点着眼于＞35岁人群

周乙华

doi:10.3969/j.issn.1001-5256.2021.07.007

慢性HBV感染免疫耐受期应重新评估诊断标准并将研究重点着眼于＞35岁人群

DOI: 10.3969/j.issn.1001-5256.2021.07.007

周乙华^,

南京大学医学院附属鼓楼医院感染科，南京 210008

利益冲突声明：作者声明不存在利益冲突。

详细信息

通信作者:
周乙华，zgr03summer@126.com

中图分类号: R512.62
计量
- 文章访问数: 479
- HTML全文浏览量: 94
- PDF下载量: 88
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-20
- 录用日期: 2021-05-28
- 出版日期: 2021-07-20

Diagnostic criteria should be reevaluated in immune-tolerant phase of chronic hepatitis B virus infection and research should be focused on the population aged > 35 years

Yihua ZHOU^,

Department of Infectious Diseases, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 免疫耐受 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Immune Tolerance /
- Therapeutics

HTML全文

参考文献(12)

[1]	CUI F, SHEN L, LI L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772. DOI: 10.3201/eid2305.161477.
[2]	LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741.
[3]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[4]	KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134(5): 1376-1384. DOI: 10.1053/j.gastro.2008.02.075.
[5]	van WOLLEGHEM T, HOU J, van OORD G, et al. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells[J]. Hepatology, 2015, 62(1): 87-100. DOI: 10.1002/hep.27805.
[6]	HONG M, BERTOLETTI A. Tolerance and immunity to pathogens in early life: Insights from HBV infection[J]. Semin Immunopathol, 2017, 39(6): 643-652. DOI: 10.1007/s00281-017-0641-1.
[7]	SONNEVELD MJ, BROUWER WP, HANSEN BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis[J]. Aliment Pharmacol Ther, 2020, 52(8): 1399-1406. DOI: 10.1111/apt.16067.
[8]	ZENG HM, HAO J, CAO MM, et al. Trend analysis of age of diagnosis for liver cancer in cancer registry areas of China, 2000-2014[J]. Chin J Prev Med, 2018, 52(6): 573-578. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.004. 曾红梅, 赫捷, 曹毛毛, 等. 2000—2014年中国肿瘤登记地区肝癌发病年龄变化趋势分析[J]. 中华预防医学杂志, 2018, 52(6): 573-578. DOI: 10.3760/cma.j.issn.0253-9624.2018.06.004.
[9]	WEI KP, ZHU FC, LIU JX, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study[J]. Vaccine, 2018, 36(2): 256-263. DOI: 10.1016/j.vaccine.2017.11.037.
[10]	LOU HQ, ZHU JH, WANG ZH, et al. Real-world efficacy of immunoprophylaxis against mother-to-infant transmission of hepatitis B virus based on puerperant population[J]. Chin J Perinat Med, 2019, 22(8): 591-596. DOI: 10.3760/cma.j.issn.1007-9408.2019.08.011. 娄海琴, 朱继华, 王志红, 等. 以产妇人群为基础的免疫预防乙型肝炎病毒母婴传播的现实世界效果[J]. 中华围产医学杂志, 2019, 22(8): 591-596. DOI: 10.3760/cma.j.issn.1007-9408.2019.08.011.
[11]	HUANG H, XU C, LIU L, et al. Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus[J]. Clin Infect Dis, 2020. DOI: 10.1093/cid/ciaa898.[Online ahead of print]
[12]	HU Y, FENG Z, LIU J, et al. Virological determinants of spontaneous postpartum e antigen seroconversion and surface antigen seroclearance in pregnant women infected with hepatitis B virus[J]. Arch Med Res, 2016, 47(3): 207-213. DOI: 10.1016/j.arcmed.2016.06.008.